UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results